So far, the Ayala Center Phase II-B is the largest expansion activity done by CHI, aside from the building of The Terraces, and other mini-improvements and expansion programs that it has embarked ...

Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the Independent Data Monitoring Committee (IDMC) for its Phase 2/3 RINGSIDE study evaluating ...

CEBU, Philippines - Ayala Center Cebu (ACC) is set to kick off with its major expansion in the first quarter of this year, the construction will cover the Phase 2-B project of the mall.

AL101 is an investigational small molecule Gamma Secretase Inhibitor (GSI) that is designed to potently and selectively inhibit Notch 1, 2, 3 and 4, and is currently being evaluated in two Phase 2 ...

“The assets being acquired from Ayala complete OS Therapeutics’ ownership ... “With compelling Phase 2b osteosarcoma data, the anticipated FDA approval of OST-HER2, and the potential to ...

The Pennsylvania-based biotech is paying $20 million in upfront cash and $30 million in common stock to Ayala Pharmaceuticals to secure the phase 3 oral gamma secretase inhibitor AL102.

today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, that patient enrollment has been completed in the Phase 3 RINGSIDE study ...